FIELD: medicine.
SUBSTANCE: methods of the invention include administration of therapeutically effective doses of dabrafenib and trametinib. The composition of the invention comprises a combination of dabrafenib and trametinib.
EFFECT: application of inventions allows to improve disease-free survival in patients with melanoma.
8 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| COMPOUND FOR TREATING CANCER | 2014 |
|
RU2708247C2 |
| COMBINED THERAPY PAC-1 | 2016 |
|
RU2720509C2 |
| USE OF ANTISENSE OLIGONUCLEOTIDE 5'-AGCTATCTCCG-3' FROM MOUSE MELANOMA GLUCOSE-6-PHOSPHATE DEHYDROGENASE GENE AS AN ANTITUMOR COMPOUND | 2021 |
|
RU2798243C1 |
| PHARMACEUTICAL COMBINATIONS | 2017 |
|
RU2759669C2 |
| TREATMENT REGIMEN FOR BREAST CANCER USING NERATINIB | 2019 |
|
RU2804713C2 |
| PROCESS FOR TREATMENT OF BREAST CANCER USING NERATINIB | 2014 |
|
RU2685715C2 |
| APILIMOD COMPOSITION AND METHODS OF USING IT IN TREATING MELANOMA | 2015 |
|
RU2731908C2 |
| INTRAVESICAL THERAPY FOR BLADDER CANCER | 2016 |
|
RU2779543C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
